What is Mauna Kea Technologies?
Mauna Kea Technologies is a global medical device innovator specializing in real-time cellular imaging. Its flagship platform, Cellvizio, provides high-resolution, microscopic visualization of tissue during ongoing procedures, effectively bridging the gap between traditional imaging and pathology. By enabling immediate, in-vivo cellular analysis, the company empowers medical professionals to make more informed, real-time decisions, thereby improving patient outcomes and reducing the need for invasive biopsies. The firm operates at the intersection of medtech and digital health, maintaining a strong market presence through strategic partnerships and a robust intellectual property portfolio.
How much funding has Mauna Kea Technologies raised?
Mauna Kea Technologies has raised a total of $68.4M across 6 funding rounds:
Series B
$30M
Debt
$7.5M
Unspecified
$8.4M
Share Placement
$14.7M
Debt
$2.1M
Other Financing Round
$5.8M
Series B (2008): $30M with participation from Seventure Partners, Psilos Group, and Creadev
Debt (2017): $7.5M led by IPF Partners
Unspecified (2019): $8.4M supported by JJDC
Share Placement (2021): $14.7M featuring Johnson & Johnson Innovation and Armistice Capital
Debt (2025): $2.1M backed by Vester Finance
Other Financing Round (2025): $5.8M, investors not publicly disclosed
Key Investors in Mauna Kea Technologies
Psilos Group
A healthcare-focused investment firm providing venture and growth capital to companies that improve quality and reduce costs in the healthcare economy.
Seventure Partners
An active partner for innovative companies in digital technologies and life sciences, with a focus on health, nutrition, and sustainable biotechnologies.
IPF Partners
A prominent alternative financing provider specializing in tailored debt and equity solutions for the healthcare, medtech, and biopharma sectors.
What's next for Mauna Kea Technologies?
With the successful closure of its most recent financing round, Mauna Kea Technologies is well-positioned to accelerate its commercial expansion and deepen its research and development initiatives. The company is expected to focus on scaling the adoption of its Cellvizio platform in key international markets while simultaneously exploring new clinical applications for its imaging technology. As the healthcare industry increasingly prioritizes precision medicine and minimally invasive procedures, Mauna Kea Technologies remains a pivotal player in the evolution of diagnostic standards. Future strategic efforts will likely center on enhancing operational efficiencies and strengthening its competitive moat through continued technological differentiation and collaborative clinical research.
See full Mauna Kea Technologies company page
